Under the terms of the deal, San Diego-based Halozyme will receive an initial upfront payment alongside potential milestone-based compensation and royalties on net sales. Incyte has also secured an option to nominate two additional therapeutic targets for potential future integration with the ENHANZE platform, which utilizes the proprietary enzyme rHuPH20 to facilitate the subcutaneous administration of injected medications.

Dr. Helen Torley, President and CEO of Halozyme, noted that the partnership leverages Incyte’s established hematology portfolio to expand the reach of their delivery technology. The collaboration marks another addition to Halozyme’s network of partnerships with biopharmaceutical firms, including Roche, Pfizer, and Takeda, as the company seeks to reduce treatment burdens across multiple therapeutic areas.